

June 2025

## **CURRICULUM VITAE**

### **LINDA NICI, M.D.**

99 Pratt Street  
Providence, Rhode Island 02906  
Linda\_Nici@brown.edu

#### **EDUCATION**

Undergraduate: St. John's University, Jamaica, NY  
Medical Technology  
B.S., summa cum laude, 1976-1980

Medical School: State University of New York, Health Science Center at  
Brooklyn, M.D., cum laude, 1980-1984

#### **POSTGRADUATE TRAINING**

Residency: Columbia-Presbyterian Medical Center, New York, NY  
Internship and Residency, Internal Medicine, 1984 - 1987

Fellowship: Yale University School of Medicine, New Haven, CT  
Fellowship in Pulmonary & Critical Care Medicine  
1987 - 1990

#### **POSTGRADUATE HONORS AND AWARDS**

1981	Alpha Omega Alpha, Medical Honor Society
2009	Career Achievement Award- Quebec International Symposium on Cardiopulmonary Prevention and Rehabilitation
2009	Teaching Recognition Award- The Warren Alpert Medical School of Brown University
2011, 2019	The Dean's Excellence in Teaching Award- The Alpert Medical School of Brown University
2015	Beckwith Family Award for Outstanding Teaching The Warren Alpert Medical School of Brown University
2018	Thomas L. Petty Distinguished Pulmonary Scholar Award The American Association of Cardiovascular and Pulmonary Rehabilitation

## **PROFESSIONAL LICENSURES AND BOARD CERTIFICATION**

Licenses:	1986 - 1988	New York	License # 165565
	1987 - 1992	Connecticut	License # 028553
	1991 - Present	Rhode Island	License # 8016
	1991 - Present	DEA	BN2216667
Certification:	1987	American Board of Internal Medicine	
(#114431)	2010	Pulmonary Medicine Subspecialty	
		Certification	
	1991	Critical Care Medicine Subspecialty	
		Certification	

## **ACADEMIC APPOINTMENTS**

1987-1991	Instructor in Medicine Yale University School of Medicine New Haven, CT
1991 – 2002	Assistant Professor of Medicine The Alpert Medical School of Brown University Providence, RI
2002 – 2009	Clinical Associate Professor of Medicine The Alpert Medical School of Brown University Providence, RI
2009 – 2014	Clinical Professor of Medicine The Alpert Medical School of Brown University Providence, RI
2014- 2024	Professor of Medicine The Alpert Medical School of Brown University Providence, RI
2025- present	Professor Emeritus The Alpert Medical School of Brown University Providence, RI
2011- 2021	Site Director Pulmonary/Critical Care fellowship program The Alpert Medical School of Brown University Providence, RI

## **HOSPITAL APPOINTMENTS**

1991 - 1995	Staff Physician Department of Medicine Roger Williams Medical Center Providence, RI
1995 – 2004	Staff Physician Department of Medicine Rhode Island Hospital Providence, RI
2004-present	Staff Physician Department of Medicine Providence VA Medical Center Providence, RI
2004-2024	Medical Director, Pulmonary Rehabilitation Program Providence VA Medical Center Providence, RI
2004-2024	Director of Respiratory Therapy Providence VA Medical Center Providence, RI
2006-2011	Associate Chief, Pulmonary and Critical Care Division Providence VA Medical Center Providence, RI
2011-2024	Chief, Pulmonary and Critical Care Division Providence VA Medical Center Providence, RI
2014- 2024	VISN Lead for Pulmonary/Critical Care Medicine VISN 1 – Veterans Affairs Medical Centers

## **OTHER APPOINTMENTS**

1995 – 1999	Co- Medical Director Meeting Street Center Outpatient Pulmonary Rehabilitation Program
-------------	--

1995 - 1999	Program Committee Member: American Thoracic Society Assembly on Respiratory Cell & Molecular Biology
1995 – 2009	Medical Director, Sub-Acute Unit Oak Hill Nursing & Rehabilitation Center, Pawtucket, RI
1998-present	Member: American Thoracic Society Assembly on Clinical Problems
2009-present	Member: American Thoracic Society Pulmonary Rehabilitation Assembly
1998-2009	Planning Committee Member: American Thoracic Society Section on Pulmonary Rehabilitation
1999-2004	Member: Task Force on Women & Girls, Tobacco, & Lung Cancer; American College of Chest Physicians
2000-2001	Rhode Island Thoracic Society: Secretary/Treasurer (2000-01); Vice President (2001-2002); President (2002-2004)
2001-2003	President Board of Directors Occupational and Environmental Center of RI
2001 and 2009	Writing Committee Member: Guidelines for Pulmonary Rehabilitation Programs American Association of Cardiovascular & Pulmonary Rehabilitation
2002-2006	Co-Chair: Joint American Thoracic Society/ European Respiratory Society Statement on Pulmonary Rehabilitation
2003-2005	Board of Directors, American Lung Association of RI
2003-present	Editorial Board: Chronic Respiratory Disease
2004-2005	Scientific Advisory Board, Task Force: Chronic Disease Management American Association of Cardiovascular and Pulmonary Rehabilitation
2004-present	Editorial Board: US Respiratory Disease
2005-2006	Board of Directors

American Association of Cardiovascular and Pulmonary  
Rehabilitation

2007-2009	Pulmonary Rehabilitation Assembly Inaugural Chair American Thoracic Society
2007-2009; 2010-14	Board of Directors American Thoracic Society
2007-2019	Scientific Advisory Board; CIRO Horn Centre for Rehabilitation in Chronic Organ Failure; Maastricht, the Netherlands
2009-2014	Council of Chapter Representatives: Rhode Island Thoracic Society Representative (2009-present); Secretary-Treasurer, (2010-11), Chair-elect (2011-12), Chair (2012-13), Immediate Past-Chair (2013-2014), American Thoracic Society
2011-2013	Writing Committee Member: American Thoracic Society/ European Respiratory Society Statement on Pulmonary Rehabilitation
2011-2013	Member- Research Advocacy Committee; Co-Chair- VA Research Sub-committee American Thoracic Society
2012- 2023	Board of Trustees The Foundation of the American Thoracic Society
2013- 2016	Chair Research Advocacy Committee American Thoracic Society
2013-2018	Presidential appointee Planning and Evaluation Committee American Thoracic Society
2014-2015	Member- Nominating Committee American Thoracic Society
2015- 2016	Secretary-Treasurer The Foundation of the American Thoracic Society
2016-2023	Vice-Chair The Foundation of the American Thoracic Society
2019- 2020	Co-chair

ATS Clinical Practice Guidelines on the Pharmacotherapy of  
COPD

2019- present	Editorial Board CHEST COPD specialty group
Ad Hoc Reviewer for:	American Journal of Physiology: Lung Cellular & Molecular Physiology American Journal of Respiratory and Critical Care Medicine Annals of the American Thoracic Society European Respiratory Journal Lung Cancer American Journal of Pathology Journal of Cardiopulmonary Rehabilitation Respiratory Medicine Thorax Chest COPD International Journal of COPD Chronic Respiratory Disease

**HOSPITAL COMMITTEES**

1991 - 1995	Roger Williams Medical Center - Library Committee - Department of Medicine, Research Committee - Continuing Medical Education (CME) Committee
1998- 2004	Lifespan and the Rhode Island Hospital - Council for the Arts in Medicine
2004-2006	System Redesign Initiative Providence VAMC
2009-2010	COPD Clinical Platforms task force VISN 1- Veterans Affairs Administration
2010-2024	Quality Assurance Committee Providence VAMC
2013- 2014	VISN 1 E-Consult Workgroup Providence Veterans Affairs Medical Center
2013- 2014	VA Strategic Planning Access Sub-group Providence Veterans Affairs Medical Center

2015- 2024	Strategic Planning Committee Providence VA Medical Center Providence, RI
2017- 2019	Life sustaining treatment initiative Providence VA Medical Center Providence, RI
2017- 2024	VISN 1 Lung Cancer Council

### **UNIVERSITY COMMITTEES**

1992 - 2000	Coordinator Brown-Wide Pulmonary Grand Rounds The Alpert Medical School of Brown University
2010- 2022	Clinical Faculty Advisory Committee The Alpert Medical School of Brown University
2014- 2022	Medical Faculty Executive Committee ( <i>ex officio member</i> ) The Alpert Medical School of Brown University
2018- 2020	Chair, Clinical Faculty Advisory Committee The Alpert Medical School of Brown University

### **MEMBERSHIP IN SOCIETIES**

1984 - 1987	Member, American College of Physicians
1987 - 1993	Member, American College of Chest Physicians
1987 - Present	Member, American Thoracic Society
1987 - Present	Member, American Lung Association of Rhode Island
1991 – 2023	Member, Rhode Island Thoracic Society
2001-Present	Member, American Association for Cardiovascular and Pulmonary Rehabilitation

### **PUBLICATIONS** **(original, peer-reviewed)**

- 1) Heffner JL, Coggeshall S, Wheat CL, Krebs P, Feemster LC, Klein DE, **Nici L**, Johnson H, Zeliadt SB. Receipt of Tobacco Treatment and One-Year Smoking Cessation Rates Following Lung Cancer Screening in the Veterans Health Administration. *Journal of General Internal Medicine*. DOI 10: 1007/s116060-021-07011-0, 2022.
- 2) Vayntrub Y, Gartman E, **Nici L**, Jankowich MD. Diagnostic performance of the Herder model in veterans undergoing PET scans for pulmonary nodule evaluation. *Lung* 199(6):653-657, 2021
- 3) Gartman E, Jankowich M, Baptiste J, Schiff A, **Nici L**. Outcomes of the first three years of a lung cancer screening program at a Veterans Affairs Medical Center. *Ann Am Thorac Soc*. 2018 Nov;15(11):1362-1365
- 4) Okereke IC, Bates MF, Jankowich MD, Rounds SI, Kimble BA, Baptiste JV, Ng TT, **Nici L**. Effects of Implementation of Lung Cancer Screening at One Veterans Affairs Medical Center. *Chest*. 150(5):1023-1029, 2016
- 5) Clark N, Fan VS, Slatore CG, Locke E, Whitson HE, **Nici L**, Thielke SM. Dyspnea and pain frequently co-occur among medicare managed care recipients. *Ann Am Thorac Soc*. 11(6):890-897, 2014.
- 6) Pirraglia,P, Casserly B, Velasco R, **Nici L**. Association of Change in Depression and Anxiety Symptoms with Functional Outcomes in Pulmonary Rehabilitation Patients. *J Psychosom Res*.71(1):45-9, 2011
- 7) Velasco R, Pirraglia PA, Casserly B, **Nici L**. The Influence of Body Mass Index on Changes in Disease-Specific Quality of Life of Veterans Completing Pulmonary Rehabilitation. *J Cardiopulm Rehab and Prevention*. 30(5):334-9, 2010.
- 8) Sartore-Bianchi A, Gasparri F, Galvani A, **Nici L**, et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. *Clin Cancer Res*.13(19):5942-51, 2007.
- 9) **Nici L**, Monfils B, Calabresi P. The Effects of Taurolidine on Human Malignant Mesothelioma. *Clin Cancer Res*. 10(22):7655-61, 2004.



- 10) **Nici L**, Monfils B, Calabresi P. Modulation of Bleomycin-Induced Pulmonary Toxicity in the Hamster by L- Carnitine, J of Appl Res. 1(2): 158-166, 2001.
- 11) **Nici L**, Calabresi P. Amifostine modulation of bleomycin-induced lung injury in rodents. Seminars in Oncology; 26 (2) Suppl 7: 28-33, 1999.
- 12) **Nici L**, Kuhn C, Calabresi P. Modulation of Bleomycin Induced Pulmonary Toxicity in the Hamster by the Antioxidant, Amifostine. Cancer; 83:2008-14, 1998.
- 13) **Nici L**, Medina M, Frackleton AR Jr. The Epidermal Growth Factor Receptor Network in Type 2 Pneumocytes Exposed to Hyperoxia *In Vitro*. Am J Physiol (Lung Cell Mol. Physiol.) 14:L242-L250, 1996.
- 14) Ingbar, DH, Hepler K, Dowin R, Jacobson E, **Nici L**, Wangenstein OD. Gamma-Glutamyl Transpeptidase is a Polarized Alveolar Epithelial Membrane Protein. Am J Physiol 269 (Lung Cell Mol. Physiol. 13):L261-L271, 1995.
- 15) Carter, EP, Duvick SE , Wendt CH , Duntiz J, **Nici L**, Wangenstein OD, Ingbar DH . Hyperoxia Increases Active Alveolar Na<sup>+</sup> Resorption *In Vivo* and Type II Cell NA, K-ATPase *In Vitro*. Chest 105:755-785, 1994.
- 16) **Nici L**, Dowin R, Gilmore-Hebert M, Jamieson JD, Ingbar DH. Upregulation of Rat Lung NA, K-ATPase During Hyperoxic Injury. Am. J. Physiol. 261 (Lung Cell Mol. Physiol. 5):L307-L314, 1991.
- 17) **Nici L**, Dowin R, Gilmore-Hebert M, Jamieson JD, Ingbar DH. Response of Rat Type II pneumocyte Na, K-ATPase to Hyperoxic Injury. Chest 99: 31S-33S, 1991

## **PUBLICATIONS**

**(other, peer-reviewed)**

- 1) Lareau S, ZuWallak R, **Nici L**. Increasing quality and quantity of life in individuals with chronic obstructive pulmonary disease: a narrative review with an emphasis on pulmonary rehabilitation. Life (Basel); 7(15): 750. Doi: 10.3390, 2025.

- 2) Moy ML, Bhatt SP, Casaburi R, Garvey C, **Nici L**. Not all tele-pulmonary rehabilitation models for chronic respiratory disease are created equal. *Chest*; 167(5): e169-e170, 2025.
- 3) Press VG, **Nici L**. Improving pulmonary rehabilitation: It's time to examine the system. *Ann Am Thorac Soc*; 21(12):1655-1656, 2024.
- 4) Goldstein R, Jardim JR, **Nici L**, Raskin J, Spruit MA, ZuWallack R. The importance of addressing physical activity and exercise intolerance in our patients with COPD. *Breathe*; 20(2):230272. doi: 10.1183/20734735.0272-2023, 2024
- 5) Vales AW, Burtin C, Casaburi R, Celli BR, Evans RA, Lareau SC, **Nici L**, Rochester CL, Troosters T. Prevalence and prognostic importance of exercise limitation and physical inactivity in COPD. *Breathe*; 20(2):230179. doi: 10.1183/20734735.0179-2023, 2024
- 6) Tang CY, Bernstein B, Blackstock F, Blondeel A, Gershon A, Gimeno-Santos E, Gloeckl R, Marques A, Spruit MA, Garvey C, Morgan M, **Nici L**, Singh SJ, Troosters T. Unraveling the complex interplay of factors behind exercise limitations and physical inactivity in COPD. *Breathe*; 20(2):230180. doi: 10.1183/20734735.0180-2023, 2024
- 7) **Nici L**. Pulmonary Rehabilitation: Mechanisms of Functional Loss and Benefits of Exercise. *Respir Care*. Mar 19: doi: 10.4187/respcare.11705, 2024
- 8) Agusti A, Ambrosino N, Blackstock F, Bourbeau J, Casaburi R, Celli B, Crouch R, Negro RD, Dreher M, Garvey C, Gerardi D, Goldstein R, Hanania N, Holland AE, Kaur A, Lareau S, Lindenauer PK, Mannino D, Make B, Maltais F, Marciniuk JD, Meek P, Morgan M, Pepin JL, Reardon JZ, Rochester C, Singh S, Spruit MA, Steiner MC, Troosters T, Vitacca M, Clini E, Jardim J, **Nici L**, Raskin J, ZuWallack R. COPD: Providing the right treatment for the right patient at the right time. *Respir Med*.doi: 10.1016/j.rmed.2022.107041, 2023.
- 9) **Nici L**. Improving the lives of individuals with chronic respiratory disease: the need for innovation. *Thorax*; doi: 10.1136/thoraxjnl-2021-218318, 2022.
- 10) **Nici L**. Pulmonary rehabilitation after a COPD exacerbation: impact on readmission risk in a real-world setting. *Am J*

Respir Crit Care Med. doi: 10.1164/rccm.202107-1768ED,  
2022

- 11) Donner CF, ZuWallack R, **Nici L**. The role of telemedicine in extending and enhancing medical management of patients with chronic obstructive pulmonary disease. *Medicina*; 57(7): 726. doi: 10.3390/medicina 57070726, 2021.
- 12) Holland AE, Cox NS, Houchen-Wolloff L, Rochester CL, Garvey C, ZuWallack R, **Nici L** et al. Defining modern pulmonary rehabilitation: an official American Thoracic Society workshop report. *Ann Am Thorac Soc*; 18 (5): e12–e29, 2021.
- 13) Gartman EJ, Mulpuru SS, Mammen MJ, Alexander PE, **Nici L**, Aaron SD et al. Summary for clinicians: clinical practice guideline on pharmacologic management of chronic obstructive pulmonary disease. *Ann Am Thorac Soc*; 18(1): 11-16, 2021.
- 14) Mammen MJ, Lloyd DR, Kumar S, Ahmed AS, Pai V, Kunadharaju R, Gupta S, **Nici L**, Aaron SD, Alexander PE. Triple Therapy versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis. *Ann Am Thorac Soc*; 17(10): 1308-1318, 2020.
- 15) Wilson KC, Kaminsky DA, Michaud G, Sharma S, **Nici L**, et al. Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens: From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Society-coordinated Task Force. *Ann Am Thorac Soc*. 17(11):1343-1351, 2020.
- 16) Mammen MJ, Pai V, Aaron SD, **Nici L**, Alhazzani W, Alexander PE. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for COPD: A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. *Ann Am Thorac Soc*. 17(9): 1133-1143, 2020.
- 17) **Nici L**, Mammen MJ, Charbek E, Alexander PE, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*; 201(9), 2020.

- 18) **Nici L**, Singh SJ, Holland AE, ZuWallack RL. Opportunities and challenges to expanding pulmonary rehabilitation into the home and community. *Am J Respir Crit Care Med*; 200(7): 822–827, 2019
- 19) Blackstock FC, Lareau SC, **Nici L**, ZuWallack R et al. Chronic Obstructive Pulmonary Disease Education in Pulmonary Rehabilitation. An Official American Thoracic Society/Thoracic Society of Australia and New Zealand/Canadian Thoracic Society/British Thoracic Society Workshop Report. *Ann Am Thorac Soc*. 15(7):769-784, 2018.
- 20) Spruit MA, Singh SJ, Rochester CL, Greening NJ, Franssen FME, Pitta F, Troosters T, Nolan C, Vogiatzis I, Clini EM, Man WD, Burtin C, Goldstein RS, Vanfleteren LEGW, Kenn K, **Nici L**, Janssen DJA, Casaburi R, Shioya T, Garvey C, Carlin BW, ZuWallack RL, Steiner M, Wouters EFM, Puhon MA. Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future? *Eur Resp J*. 51(1), 2018.
- 21) Macrea M, ZuWallack R, **Nici L**. There's no place like home: Integrating Pulmonary Rehabilitation into the Home Setting. *Monaldi Arch Chest Dis*. 18;87(2):859, 2017
- 22) Effing TW, Vercoulen JH, Bourbeau J, Trappenburg J, Lenferink A, Cafarella P, Coultas D, Meek P, van der Valk P, Bischoff EW, Bucknall C, Dewan NA, Early F, Fan V, Frith P, Janssen DJ, Mitchell K, Morgan M, **Nici L**, Patel I, Walters H, Rice KL, Singh S, Zuwallack R, Benzo R, Goldstein R, Partridge MR, van der Palen J. Definition of a COPD self-management intervention: International Expert Group consensus. *Eur Respir J*. 48(1):46-54. 2016
- 23) Blackstock FC, ZuWallack R, **Nici L**, Lareau SC. Why don't our COPD Patients listen to us? The enigma of nonadherence. *Ann Am Thorac Soc*. 13(3):317-23, 2016
- 24) Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhon MA, Spruit MA, Masfield S, Casaburi R, Clini EM, Crouch R, Garcia-Aymerich J, Garvey C, Goldstein RS, Hill K, Morgan M, **Nici L**, Pitta F, Ries AL, Singh SJ, Troosters T, Wijkstra PJ, Yawn BP, ZuWallack RL. An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary

Rehabilitation. Am J Respir Crit Care Med.192(11):1373-86, 2015.

- 25) **Nici, L** and ZuWallack R. Chronic obstructive pulmonary disease-evolving concepts in treatment: advances in pulmonary rehabilitation. Semin Respir Crit Care Med. 36; 567-574, 2015.
- 26) Spruit MA, Pitta F, McAuley E, ZuWallack R, **Nici L**. Pulmonary rehabilitation and physical activity in patients with COPD. Am J Respir Crit Care Med. 192(8):924-33, 2015.
- 27) **Nici L**, ZuWallack R. Pulmonary rehabilitation for patients with chronic airways obstruction. J Allergy Clin Immunol Pract. 3(4):512-518. 2015
- 28) Collins EG, Bauldoff G, Carlin B, Crouch R, Emery CF, Garvey C, Hilling L, Limberg T, ZuWallack R, **Nici L**. Clinical competency guidelines for pulmonary rehabilitation professionals: Position statement of the American Association of Cardiovascular and Pulmonary Rehabilitation. J Cardiopulm Rehab Prev;34(5):291-302, 2014.
- 29) **Nici L**, Bontley T, ZuWallack R, Gross N. Self - management in COPD: time for a paradigm shift? Ann Am Thorac Soc. 11(1):101-7, 2014.
- 30) Spruit, MA, Garvey C, Singh S, ZuWallack R, **Nici L**, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 188(8):13-64, 2013.
- 31) Singh SJ, ZuWallack RL, Garvey C, Spruit MA; American Thoracic Society/European Respiratory Society Task Force on Pulmonary Rehabilitation. Learn from the past and create the future: the 2013 ATS/ERS statement on pulmonary rehabilitation. Eur Respir J; 42(5):1169-1174, 2013
- 32) Holland AE, **Nici L**. The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 187(4):335-6, 2013.
- 33) **Nici L**. Adherence to a pulmonary rehabilitation program: start by understanding the patient. COPD. 9(5):445-6, 2012.

- 34) ZuWallack, R , **Nici L**. Modifying the course of COPD: looking beyond the FEV1. COPD. 2012; 9:1-12, 2012
- 35) Reticker AL, **Nici L**, Zuwallack R. Pulmonary rehabilitation and palliative care in COPD: two sides of the same coin. Chronic Resp Dis. 9(2):107-16, 2012.
- 36) **Nici L**, ZuWallack R. An Official ATS Workshop Report: The Integrated Care of the COPD Patient. Proc Am Thorac Soc. 9(1): 9-18, 2012.
- 37) **Nici L**, Lareau S, ZuWallack R. Pulmonary Rehabilitation in the treatment of chronic obstructive pulmonary disease. Am Fam Physician. 82(6): 655-660, 2010.
- 38) **Nici L**, ZuWallack R, Rochester C, Raskin J et al. Pulmonary Rehabilitation: What we know and what we need to know. J Cardiopulm Rehab and Prevention. J Cardiopulm Rehab and Prevention. 29(3): 141-151, 2009.
- 39) **Nici L**. The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles vs. lower limb muscle dysfunction vs. dynamic hyperinflation. Difficulties in determining the primary physiological abnormality that limits exercise performance in COPD. J Appl Physiol. 105(2):760-1, 2008.
- 40) **Nici L**, Limberg T, Hilling L, et al. Clinical Competencies for Pulmonary Rehabilitation Professionals. J Cardiopulm Rehab and Prevention. 27(6):355-358, 2007.
- 41) **Nici, L**. Can we make it last? Maintaining Benefits Achieved After Pulmonary Rehabilitation. Lung. 185(4): 241-242, 2007.
- 42) **Nici L**, ZuWallack R, Wouters E, Donner C. On pulmonary rehabilitation and the flight of the bumblebee: the ATS/ERS Statement on Pulmonary Rehabilitation. Eur Respir J. 28: 461-462, 2006.
- 43) **Nici,L**, Donner C, Wouters E, ZuWallack R, et al. American Thoracic Society / European Respiratory Society Statement on Pulmonary Rehabilitation. Am J Respir Crit Care Med. 173: 1390-1413, 2006.

**PUBLICATIONS**  
**(books and book chapters)**

- 1) **Nici L**, Rochester CL. Pulmonary Rehabilitation. *In: Murray and Nadel Textbook of Respiratory Medicine*. Broaddus et al, eds. Saunders Press. 2020
- 2) **Nici L**, ZuWallack R. Pulmonary Rehabilitation in the Integrated Care of Chronic Respiratory Patient. *In: Clinical Textbook of Pulmonary Rehabilitation*. Donner, Ambrosino, Goldstein, eds. CRC Press. 2020
- 3) **Nici L**, Goldstein R. Pulmonary Rehabilitation; The development of a scientific discipline. *In: Clinical Textbook of Pulmonary Rehabilitation*. Donner, Ambrosino, Goldstein, eds. CRC Press. 2020
- 4) **Nici L** and Spruit M. Current Concepts and Definitions in Textbook in Pulmonary Rehabilitation. Springer publishers. November 2017.
- 5) **Nici L** and ZuWallack R. Pulmonary Rehabilitation: future directions. *Clin Chest Med*. 35(2): 439-444, 2014.
- 6) **Nici L** and ZuWallack R. Pulmonary Rehabilitation: definitions, concept and history. *Clin Chest Med*. 35(2): 279-282, 2014
- 7) **Nici L** and ZuWallack R, *editors*. Pulmonary Rehabilitation. *Clin Chest Med*. 35(2), 2014.
- 8) **Nici, L** and ZuWallack R. Pulmonary Rehabilitation: Targeting the Systemic Manifestations of COPD *in Chronic Obstructive Pulmonary Disease: Co-morbidities and Systemic Consequences*. Springer publishers. November 2011.
- 9) **Nici, L** and ZuWallack R, *editors*. Chronic Obstructive Pulmonary Disease: Co-morbidities and Systemic Consequences. Springer publishers. November 2011.
- 10) Lan CKW, **Nici L**, ZuWallack R. Pulmonary Rehabilitation *In COPD: A Guide to Diagnosis and Clinical Management*. Hanania NA ed. Humana Press, June 2010.
- 11) **Nici, L** and ZuWallack R. Pulmonary Rehabilitation. *In Atlas of Pulmonary Medicine*. Crapo, J, ed. Springer. 2009.
- 12) **Nici, L**. Selection and Assessment of the Pulmonary Rehabilitation Candidate. *In Pulmonary Rehabilitation: Guidelines to Success*, Fourth Edition. Hodgkin JE, Celli BR, Connors GL, eds. Mosby Elsevier. 2009.

- 13) **Nici, L.** Preoperative and Postoperative Cardiopulmonary Rehabilitation. *In Thoracic Surgery Clinics*. 18(1); 39-44, 2008.
- 14) Stone, AC and **Nici L.** Other Systemic Manifestations of COPD. *In Clinics in Chest Medicine*. 28: 553-557, 2007.
- 15) **Nici L.** Selection and Assessment of the Pulmonary Rehabilitation Candidate. *In Guidelines for Pulmonary Rehabilitation Programs*. Third Edition. ZuWallack RL and Crouch R eds. Human Kinetics 2004.
- 16) **Nici L.** Mechanisms and Measures of Exercise Intolerance in COPD. *In Clinics in Chest Medicine*. 21(4);693-704, 2000.
- 17) Ingbar DH and **Nici L.** Respiratory Therapy and Monitoring. *In Stein's Internal Medicine*, 5th Edition, 1997.
- 18) Zitnik RJ, **Nici L**, Ingbar DH. Mechanisms of Alveolar Injury and Repair. *In Annual Review of Pulmonary and Critical Care Medicine*. Matthay RA, ed. 175-192, 1991/1992.

## **PUBLICATIONS**

**(other non-peer review)**

- 1) **Nici L**, ZuWallack R, Donner C, eds. Special Issue: Utilizing telemedicine as a tool to enhance outcomes in Individuals with chronic respiratory diseases. *Life (Basel)*. Doi: 10.3390/life12030425, 2022.
- 2) Mammen MJ, Charbek E, Alexander PE, **Nici L**, Aaron SD. Reply to: Opioids for dyspnea in COPD: short on details. *Am J Respir Crit Care Med*. Doi: 10.1164/rccm.202009-3605LE, 2020
- 3) **Nici L** and Aaron SD. Reply to Mahler et al. Pharmacotherapy for chronic obstructive pulmonary disease: molecules and delivery are equally important. *Am J Respir Crit Care Med*; 202(10): 1482-1483, 2020
- 4) **Nici L**, Singh SJ, Holland AE, ZuWallack RL. Reply to: Prieto-Centurion et al.: Patients with COPD require more than pulmonary rehabilitation to improve outcomes. *Am J Respir Crit Care Med*. 200(12): 1555-1556, 2019.
- 5) **Nici L.** Improving uptake of pulmonary rehabilitation after a chronic obstructive pulmonary disease exacerbation. *Ann Am Thorac Soc*; 16(9): 1119-1121. 2019.



- 6) Donner C, Raskin J, ZuWallack R, **Nici L**, et al. Incorporating telemedicine into the integrated care of the COPD patient a summary of an interdisciplinary workshop held in Stresa, Italy, 7–8 September 2017. *Respiratory Medicine*.143: 91-102, 2018
- 7) **Nici L**, ZuWallack R. Integrated care in COPD and rehabilitation. *COPD*;15(3):223-230, 2018
- 8) Hall C, **Nici L**, Sood S, ZuWallack R, Castro M. Nonpharmacologic therapy for severe persistent asthma. *J Allergy Clin Immunol Pract*. 5(4):928-935, 2017.
- 9) Williams L, Wilcox D, ZuWallack R, **Nici L**. Integrated care: What does this mean for the COPD patient? *Chron Obstruct Pulmon Dis* 1: 15, 2016
- 10) **Nici L** and ZuWallack R. They can't bury you while you are still moving: A review of the European Respiratory Society statement on physical activity in COPD. *Polish Archives of Internal Medicine*. *Pol Arch Med Wewn*. 28;125(10):771-8, 2015
- 11) Ambrosino N, Casaburi R, Chetta A, Clini E, Donner CF, Dreher M, Goldstein R, Jubran A, **Nici L**, Owen CA, Rochester C, Tobin MJ, Vagheggini G, Vitacca M, ZuWallack R. 8<sup>th</sup> international conference on management and rehabilitation of chronic respiratory failure: the long summaries. *Multidiscip Respir Med*; 10: 31, 2015
- 12) Peters-Golden M, Klinger JR, Carson SS; ATS Research Advocacy Committee. The case for increased funding for research in pulmonary and critical care. *Am J Respir Crit Care Med*. 186(3):213-5, 2012.
- 13) **Nici L** and ZuWallack R. Scope, background and definition of pulmonary rehabilitation. *Eur J of Phys Rehabil Med*. 47(3):465-74, 2011.
- 14) ZuWallack, R and **Nici L**. The integrated care of the COPD patient: a pulmonary rehabilitation perspective. *Breathe*; 6(4): 2010.
- 15) **Nici, L** and ZuWallack R. Pulmonary rehabilitation: today and tomorrow. *Breathe*; 6(4): 2010.
- 16) **Nici, L**. A bill of rights for patients with COPD. Commissioned editorial. *Thorax*; 65(1): 2010

- 17) Lareau S and **Nici L**. Outcome assessment in pulmonary rehabilitation. American College of Chest Physician's web-based educational program, Pulmonary and Critical Care Medicine Update (PCCU), Vol 24.
- 18) **Nici, L**. The role of pulmonary rehabilitation in the lung cancer patient. *Semin Respir Crit Care Med*. 30(6):670-4, 2009.
- 19) **Nici, L**. Guest Editor. Pulmonary Rehabilitation: Role and Advances *In Seminars in Respiratory and Critical Care Medicine*; 30(6):627-628. 2009
- 20) Decramer M, **Nici L**, Nardini S, Reardon J, Rochester CL, Sanguinetti CM, Troosters T. Targeting the COPD exacerbation. *Respir Med*. 102 Suppl 1:S3-15. 2008
- 21) Reardon J, Casaburi R, Morgan M, **Nici L**, Rochester CL. Pulmonary Rehabilitation for COPD. *Respiratory Medicine*. 99: S19-S27, 2005.
- 22) **Nici L**. Pulmonary Rehabilitation in the Treatment of Chronic Respiratory Disease. In *Business Briefings: US Respiratory Care 2005*, Touch Briefings, London, U.K. 2005.
- 23) **Nici L**. Lung Cancer Screening. *J Resp Dis*. 21(2); 117-125, 2000.

**PUBLICATIONS SUMMITTED**  
**OR IN PREPARATION**

**ABSTRACTS**

- 1) **Nici L**, Smith E. Patient Initiation of End-of-Life Discussions, a Randomized Control Trial. International Conference of The American Thoracic Society. San Francisco CA. 2022
- 2) Vayntrub Y, Gartman EJ, **Nici L**, Jankowich MD. Diagnostic Performance of the Herder Malignancy Risk Prediction Model in Veterans Undergoing PET Scans for Pulmonary Nodule Evaluation. International Conference of The American Thoracic Society. San Diego, CA. 2021
- 3) Ferguson J, Jankowich MD, **Nici L**, Melek J, Gartman EJ. Barriers to Lung Cancer Screening in a Veteran Population:

Does Distance Drive Completion? AJRCCM;201: A6456.  
2020

- 4) Schiff A, Greene S, Gartman EJ, Jankowich MD, **Nici L.** Correlation of a Co-morbidity Index with Time-to-Death from Baseline Lung Cancer Screening CT in a Veteran Population. International Conference of The American Thoracic Society. Dallas, TX. 2019
- 5) Schiff A, Gartman EJ, **Nici L.** A Pilot Study to Assess the Impact of Pulmonary Rehabilitation on Veterans with Chronic Obstructive Pulmonary Disease and Post-Traumatic Stress Disorder. International Conference of The American Thoracic Society. Dallas, TX. 2019
- 6) Gartman EJ, Jankowich MD, Baptiste J, **Nici L.** Providence VA Lung Cancer Screening Program: Performance: Comparison of Local False Positive and Invasive Procedure Rates to Published Trial Data. Presented at American Thoracic Society Meeting, San Diego, CA. Am J Respir Crit Care Med; 197: A2477. 2018
- 7) Jankowich MD, Gartman EJ, Baptiste J, **Nici L.** Histology and Staging of Lung Cancer in Veterans Who Underwent Baseline Low-Dose CT Screening: Data from the Providence VA Medical Center. Presented at American Thoracic Society Meeting, San Diego, CA. Am J Respir Crit Care Med; 197: A4416. 2018
- 8) Csikesz N, **Nici L.**, Ventetuolo C. Pulmonary rehabilitation for patients with pulmonary hypertension: A single center experience. \*Presented at the American Thoracic Society Meeting, San Francisco, CA, 2016.
- 9) Csikesz N, **Nici L.** A P. Physician-led Intervention to Prevent COPD Re-admissions. \*Presented at the American Thoracic Society Meeting, San Francisco, CA, 2016.
- 10) Csikesz N, **Nici L.** Predictors of Re-Admission After Hospitalization for Acute Exacerbation of COPD: Role of Glucocorticoid Dose and Duration. \*Presented at the American Thoracic Society Meeting, San Francisco, CA, 2016.
- 11) DuVall SL, Brown KA, **Nici L.**, Rochester CL et al. Incidence and predictors of hospital readmission among patients with chronic obstructive pulmonary disease in the

department of Veterans Affairs. \*Presented at the American College of Chest Physicians Annual Meeting, Montreal, Canada, 2016.

- 12) Parsons P, Ryan S, **Nici L**. Implementation of a Pulmonary Risk Reduction Clinic in a Veterans Affairs Medical Center. \*Presented at the American Thoracic Society Meeting, San Francisco, CA, 2012.
- 13) Bagegni B, Casserly B, **Nici L**, Pirraglia P. Predictors of change in 6 minute walk distance in COPD patients following pulmonary rehabilitation. \*Presented at the American Thoracic Society Meeting, New Orleans, LA, 2010.
- 14) Velasco R, **Nici L**, Casserly B, Pirraglia P. The Influence of body mass index on changes in disease-specific quality of life of veterans completing pulmonary rehabilitation. \*Presented at the American Thoracic Society Meeting, Toronto, 2008.
- 15) Pirraglia PA, Casserly B, Velasco R, **Nici L**. Association of change in depression and anxiety symptoms with functional outcomes in pulmonary rehabilitation patients. \*Presented at Society of Gen Intern Med Meeting, Pittsburgh 2008
- 16) Pirraglia PA, Casserly B, **Nici L**. Change in depression and anxiety symptom burden after pulmonary rehabilitation in veterans with chronic obstructive pulmonary disease. J of Gen Intern Med, 22(Supplement 1):15, 2007.
- 17) Casserly B, Pirraglia P, **Nici L**. Improvement in depression and anxiety burden after pulmonary rehabilitation in patients with chronic lung disease. Am J Resp and Crit Care Medicine. 175; A852. \*Presented at the American Thoracic Society Meeting, San Francisco, CA 2007.
- 18) Casserly B, Pirraglia P, **Nici L**. Do improvements in dyspnea and exercise tolerance correlate with changes in depression and anxiety indices in COPD patients after pulmonary rehabilitation? Am J Resp and Crit Care Medicine. 175; A234. \*Presented at the American Thoracic Society Meeting, San Francisco, CA 2007.
- 19) Stone AC, Klinger JR, **Nici L**. The IC/TLC Ratio is a Better Predictor of Right Ventricular Dysfunction and/or Pulmonary Hypertension than FEV1 in COPD Patients Undergoing Pulmonary Rehabilitation. Am J Resp and Crit

Care Medicine. 175; A716. \*Presented at the American Thoracic Society Meeting, San Francisco, CA 2007.

- 20) Stone AC, **Nici L**, Klinger JR. Pulmonary hypertension impairs ability of COPD patients to improve functional capacity during pulmonary rehabilitation. Am J Resp and Crit Care Medicine. 175; A715. \*Presented at the American Thoracic Society Meeting, San Francisco, CA 2007.
- 21) Santore-Bianchi A, **Nici L**, Porta C, et. al. The combination of the novel camptothecin analogue Gimatecan (ST1481) plus the proteasome inhibitor PS341 produces an enhanced pro-apoptotic effect in a malignant mesothelioma cell line. Proc. Am. Assoc. Can. Res. 44:742, 2003.\* Presented at the American Association for Cancer Research Annual Meeting, Washington DC 2003
- 22) **L Nici**, Monfils B, Carminati P, Calabresi P. Antineoplastic Effects of ST1481, A Novel Camptothecin, on Human Malignant Mesothelioma. Proceedings of the American Association for Cancer Research 43:1232, 2002. \*Presented at the American Association for Cancer Research Annual Meeting, San Francisco, CA 2002.
- 23) **Nici L**, Monfils B, Calabresi P. The Effects of Taurolidine on Human Malignant Mesothelioma. Proceedings of the American Association for Cancer Research 42:1012, 2001. \*Presented at the American Association for Cancer Research Annual Meeting, New Orleans, LA 2001.
- 24) **Nici L**, Santos-Moore A, Calabresi P. The Effects of the Epidermal Growth Factor Receptor (EGFR) Network on the Growth of Human Lung Cancer Cell Lines. Am J Resp and Crit Care Medicine 157(3):A325, 1998. \*Presented at the American Thoracic Society Annual Meeting, Chicago. IL 1998.
- 25) **Nici L**, Kuhn C, Calabresi P. Modulation of Bleomycin-Induced Lung Injury by the Antioxidant, Amifostine. \*Presented at the New England Cancer Society Annual Meeting, Hanover, NH, 1996.
- 26) **Nici L**, Medina M, Frackleton AR Jr., Cultured Rat Type II Pneumocytes Secrete Ligand Capable of Stimulating the Epidermal Growth Factor (EGF) Receptor. Am J Resp and Crit Care Medicine 149(5):A28, 1994. \*Presented at the

American Thoracic Society Annual Meeting, Boston, MA  
1994.

- 27) Marinelli W, **Nici L**, Chiang L, Peterson M, Carter E, Ingbar DH. Heat Shock Protein Gene Expression Following Hyperoxic Lung Injury. \*Presented at the Annual Thomas L. Petty Aspen Lung Conference, Aspen, CO, 1993.
- 28) Ingbar DH, Duvick S, Wendt CH, **Nici L**. Hyperoxia Increases Type II Cell Na, K-ATPase In Vitro. Am. Rev. Resp. Dis. 147(4):A1007, 1993. \*Presented at the American Thoracic Society Annual Meeting, San Francisco CA, 1993.
- 29) **Nici L**, Frackleton AR Jr., Functional Epidermal Growth Factor (EGF) Receptors Persist on Type II Pneumocytes Exposed to Hyperoxia *In Vitro*. Am Rev Resp Dis. 145(4):A137, 1992. \*Presented at the American Thoracic Society Annual Meeting, Miami, FL, 1992.
- 30) **Nici L**, Jacobsen E, Nathanson M, Ingbar DH. Polarized Distribution of Membrane Proteins in Subconfluent Primary Culture of Rat Type II pneumocytes. J Cell Biol. 115(3):65a, 1991. \*Presented at the American Society for Cell biology Annual Meeting, Boston, MA, 1991.

#### **SCHOLARLY WORK PUBLISHED IN OTHER MEDIA**

- 1) Editorial Consultant for “Update on Pulmonary Rehabilitation”. Physician’s Information and Education Resource (PIER). American College of Physicians. 2006-
- 2) Content Editor for Dynamed Online Expert Content. COPD subsection. 2017-present

#### **INVITED PRESENTATIONS**

- 1) Speaker: Seminar: “Predicting Survival in ARDS”, American Thoracic Society International Conference, San Francisco, California - May 1993 (**national**)

- 2) Lecture: "ARDS - Scientific Perspective", Catholic Institute of Lille, Faculte Libre de Medicine Grand Rounds, Lille, France - July 1994 (**international**)
- 3) Lecture: "ARDS - Scientific Insights", Roger Williams Medical Center, Department of Medicine Grand Rounds, August 1994 (**regional**)
- 4) Lecture: "Pulmonary Rehabilitation - What Is It, Does It Work?", Rhode Island Hospital, Department of Medicine Grand Rounds, December 1995 (**regional**)
- 5) Speaker: Postgraduate Course: Planning a Career in Pulmonary Medicine, "Balancing a Career and Family", American Thoracic Society International Conference, New Orleans, Louisiana - May 1996 (**national**)
- 6) Chair: Symposium: "Epithelial Response to Injury", American Thoracic Society International Conference, New Orleans, Louisiana - May 1996 (**national**)
- 7) Chair: Mini-Symposium: "Cellular and Molecular Aspects of Lung Cancer", American Thoracic Society International Conference, San Francisco, CA - May 1997 (**national**)
- 8) Speaker: Seminar: "Lung Cancer: Pathogenesis and Work-up", American Thoracic Society International Conference, San Francisco, CA - May 1997 (**national**)
- 9) Chair: Symposium: "Clinical Implications of Molecular Biology for the Diagnosis and Treatment of Lung Cancer", American Thoracic Society International Conference, Chicago, IL- April 1998. (**national**)
- 10) Speaker: Symposium "Mother's Health, Nation's Wealth", "Women and Lung Cancer", American College of Chest Physicians, Chicago, IL – November 1999 (**national**)
- 11) Lecture: "Women and Lung Cancer", Memorial Sloan-Kettering Medical Grand Rounds, January 2000 (**national**)
- 12) Chair: Poster Discussion Session- "Topics in Pulmonary Rehabilitation", American Thoracic Society International Conference, Toronto, Ontario – May 2000 (**national**)
- 13) Facilitator Thematic Poster Session- "Lung Cancer: Molecular Mechanisms and Gene Transfer", American Thoracic Society

International Conference, Toronto, Ontario – May 2000  
(**national**)

- 14) Lecture: “Women and Lung Cancer”, Rhode Island Lung Association Annual Meeting, June 21, 2000 (**regional**)
- 15) Speaker: Symposium “Gender Differences in Lung Cancer Risk and Susceptibility”, American College of Chest Physicians San Francisco, CA – November 2000 (**national**)
- 16) Lecture: "Gender Differences in Lung Cancer Risk & Susceptibility", Norwalk Hospital, Pulmonary Grand Rounds, November 2000 (**regional**)
- 17) Lecture: "Lung Cancer in Women", Primary Care Update 2001, Rhode Island Academy of Family Physicians; Newport, RI; March 16, 2001 (**regional**)
- 18) Speaker: Symposium “Comprehensive Management III: Surgical Considerations in Pulmonary Rehabilitation”, American Association of Cardiovascular & Pulmonary Rehabilitation, Minneapolis, MN – September, 2001 (**national**)
- 19) Speaker: Symposium “The Effect of Pulmonary Rehabilitation on Health Care Utilization: An International Perspective”, American Thoracic Society, Atlanta. May 2002 (**national**)
- 20) Chair: Symposium “The Effects of Pulmonary Rehabilitation” American Thoracic Society, Seattle, May 2003 (**national**)
- 21) Speaker: Symposium “Women and Lung Cancer”, American Association of Cardiovascular and Pulmonary Rehabilitation, Kansas City, October 2003 (**national**)
- 22) Lecture; Yale State Chest Conference, “Women and Lung Cancer”, January 7, 2004 (**regional**)
- 23) Speaker: Symposium “ The ATS-ERS Statement on Pulmonary Rehabilitation: a preview”, European Respiratory Society, Glasgow, Scotland , September 2004 (**international**)
- 24) Speaker: “The Cutting Edge of Clinical Pulmonary Medicine in COPD” , Trevi, Italy, September 2004 (**international**)
- 25) Speaker: “ Management and Rehabilitation of Chronic Respiratory Failure”, AIMAR International Congress, Stresa, Italy, March 2006 (**international**)



- 26) Speaker: “New Views on Diagnosis and Management of COPD”, AIMAR International Congress, Stresa, Italy, September 2006 (**international**)
- 27) Speaker: “ Does Asthma have a Gender Bias”, American Lung Association of Connecticut Annual Meeting, Hartford, CT October 2006. (**regional**)
- 28) Co-chair and Speaker: “Pulmonary Rehabilitation and the Flight of the Bumblebee: Refining the Process and Broadening the Scope”; ATS Post Graduate Course, ATS International Conference, San Francisco, May 2007 (**national**)
- 29) Co-chair: “ Pulmonary rehabilitation: an update according to the new ATS/ERS guidelines”; ERS Post Graduate Course, ERS International Conference, Stockholm, Sweden, Sept 2007 (**international**)
- 30) Keynote Speaker: “Pulmonary Rehabilitation and Integrated Care: Definition and Concepts”, Pulmonary Rehabilitation: State of the Science, Ft Lauderdale, FL , Jan 2008 (**national**)
- 31) Speaker: “Exercise and Pulmonary Rehabilitation” Clinical Year in Review; ATS International Conference, Toronto, May 2008 (**national**)
- 32) Visiting Professor: International Meeting of Cardiopulmonary Rehabilitation; National Institute of Respiratory Disease (INER), Mexico City, Mexico; July 2008 (**international**)
- 33) Speaker: “the concept of integrated care of the COPD patient”, 6<sup>th</sup> International Conference on Management & Rehabilitation of Chronic Respiratory Failure; Naples, Italy 2009 (**international**)
- 34) Speaker: Thematic Lecture Series “Pulmonary Rehabilitation in COPD; American Thoracic Society International Conference, San Diego, CA 2009 (**national**)
- 35) Speaker and Co-chair: Symposium “Expanding the event horizon of pulmonary rehabilitation”; American Thoracic Society International Conference, San Diego, CA 2009 (**national**)
- 36) Speaker and Co-chair: Symposium “The comprehensive management of COPD”; American Thoracic Society International Conference, San Diego, CA 2009 (**national**)

- 37) Speaker: Thematic Lecture Series “Pulmonary Rehabilitation in COPD; American Thoracic Society International Conference, San Diego, CA 2009 (**national**)
- 38) Chair: ATS Workshop “The Integrated Care of the COPD Patient”; American Thoracic Society International Conference, San Diego, CA 2009 (**national**)
- 39) Speaker: “Pulmonary Rehabilitation and the Integrated Care of the COPD patient”, COPD –current practice guidelines and new perspectives. Jagiellonian University School of Medicine, Krakow, Poland, 2009 (**international**)
- 40) Speaker: Integrated Care of the COPD Patient. Tokyo Respiratory Care Society, Tokyo, Japan, 2010 (**international**)
- 41) Speaker: Symposium “Pulmonary rehabilitation in the lung cancer patients”. American Thoracic Society International Conference, New Orleans, LA 2010 (**national**)
- 42) Chair: ATS Workshop “The Integrated Care of the COPD Patient”; American Thoracic Society International Conference, New Orleans, LA 2010 (**national**)
- 43) Speaker: “Integrated Care of the COPD Patient”; Beth Israel; Conference on the Comprehensive Care of COPD, Miami, FL 2011 (**national**)
- 44) Speaker: “Rehabilitation in the Hospitalized COPD Patient”; Yale University Conference on the Integrated Care of the COPD Patient, New Haven, CT, 2012 (**regional**)
- 45) Speaker: “Integrated Care Concepts” and “The ATS/ERS Statement on Pulmonary Rehabilitation”; AIMAR Respiratory Conference, Turin, Italy, 2012 (**international**)
- 46) Co-Chair and organizer: “Great Cases Symposium”, American Thoracic Society International Conference, San Francisco, CA 2012 (**national**)
- 47) Speaker: “The ATS/ERS Statement on Pulmonary Rehabilitation” American Thoracic Society International Conference, San Francisco, CA 2012 (**national**)
- 48) Speaker: “The ATS/ERS Statement on Pulmonary Rehabilitation” European Respiratory Society, Amsterdam, the Netherlands, 2012 (**international**)

- 49) Co-Chair and organizer: “Great Cases Symposium”, American Thoracic Society International Conference, Philadelphia, PA 2013 (**national**)
- 50) Speaker: Advances in Pulmonary Rehabilitation. Post-graduate course, American Thoracic Society International Conference, Philadelphia, PA 2013 (**national**)
- 51) Co-Chair and organizer: “COPD- bench to bedside”. Symposium, American Thoracic Society International Conference, Philadelphia, PA 2013 (**national**)
- 52) Co-Chair and organizer: “Great Cases Symposium”, American Thoracic Society International Conference, San Diego, CA 2014 (**national**)
- 53) Co-Chair and organizer: “Lung Cancer Screening in the VA”. Symposium, American Thoracic Society International Conference, San Diego, CA 2014 (**national**)
- 54) Faculty Speaker: “Pulmonary rehabilitation and integrated care”. CME course, Improving quality through reducing healthcare utilization in COPD Mount Sinai Beth Israel Medical Center, New York, NY, 2015 (**national**)
- 55) Faculty Speaker: “ Rehabilitation in the ICU”, and Faculty Speaker, “Collaborative Self-Management” AIMAR 8<sup>th</sup> International Conference on Management and Rehabilitation of Chronic Respiratory Failure, Pescara, Italy, 2015 (**international**)
- 56) Keynote Faculty Speaker: “Pulmonary rehabilitation and Integrated Care”. Dutch Lung Centers National Meeting, Amsterdam, The Netherlands, 2015 (**international**)
- 57) Speaker: ATS workshop: “Chronic Obstructive Pulmonary Disease Education in Pulmonary Rehabilitation” American Thoracic Society International Conference, San Francisco, CA 2016 (**national**)
- 58) Speaker and Co-chair: Symposium “ A report card on education pulmonary rehabilitation; how are we doing?”; American Thoracic Society International Conference, San Francisco, CA 2016 (**national**)
- 59) Co-Chair: Mini-symposium “Advances in physical activity, pulmonary rehabilitation, and exercise training” American

Thoracic Society International Conference, Washington DC  
2017 (**national**)

- 60) Speaker: Symposium “Pulmonary rehabilitation: P4 medicine avant le letter”, in honor of the career of Professor Emile Wouters. Maastricht, the Netherlands, June 21, 2019 (**international**)
- 61) Speaker: Symposium “VA Center-Based Pulmonary Rehabilitation: challenges and opportunities” American Thoracic Society International Conference, Virtual 2021 (**national**)
- 62) Speaker: keynote “Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.” South Carolina Thoracic Society; March 12, 2022 (**national**)
- 63) Speaker: Symposium “Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.” American Thoracic Society International Conference, San Francisco, CA 2022 (**national**)
- 64) Speaker: “Reducing Mortality in COPD: Achieving the Holy Grail: *Pharmacologic Interventions and Mortality*. GOLD International Conference, Philadelphia, PA, 2023 (**national**)
- 65) Lecture: “New Perspectives on Chronic Obstructive Pulmonary Disease: *implications for prevention, early diagnosis, and intervention*.” Dr. Herbert C. Sweet Endowed Lectureship in Pulmonary Medicine. Saint Louis University, 2023 (**national**)
- 66) Speaker: “Pulmonary Rehabilitation: Mechanisms of Functional Loss and Benefits of Exercise.” 60<sup>th</sup> Respiratory Care Journal Conference- Pulmonary Rehabilitation: Current Evidence and Future Directions. St. Petersburg, FL. 2023 (**national**)
- 67) Speaker: “Development, Progression and Factors Related to Exercise Limitation and Physical Inactivity in COPD.” International Symposium on Exercise Limitation and Physical Inactivity in COPD. Stresa, Italy, 2023 (**international**)
- 68) Speaker and Co-Chair: “A New Wheel to Move Pulmonary Rehabilitation Forward: *A Hub and Spoke Model*.” American

Thoracic Society International Conference, San Diego, CA  
2024 (**national**)

## **COMMUNITY PRESENTATIONS**

- 1) “Women in Science”  
Lincoln School, Career Day  
April 1998
- 2) “Tar Wars”, National Children’s Tobacco Education  
Program  
Rhode Island Medical Society  
St. Rose of Lima School, Warwick, RI  
April 1999
- 3) “Women and Smoking- What are the Risks?”  
Wellness Center and Care New England  
January 2001
- 4) Topics in Pulmonary Medicine  
Better Breathers Club- American Lung Association  
1999-present
- 5) Creator: “Smoking Prevention Week”  
A week-long series of presentations culminating in  
National “Kick Butts Day”, Barrington Middle School,  
Barrington, RI  
2001-present
- 6) Keynote Speaker: “lung disease: State of the Nation”: RI  
Nurses’ Alumni Annual Meeting, April 2002

## **GRANTS**

- 1) The Response of Rat Na,K-ATPase to Hyperoxia  
American Lung Association of Connecticut Research and  
Training Fellowship  
\$15,000; Jan. 1989 - Dec. 1989, Principal Investigator
- 2) Mechanisms of Resolution of Pulmonary Edema in Acute  
Lung Injury  
American College of Chest Physicians /Schering  
Corporation Research and Training Fellowship  
\$15,000; April 1989 -March 1990, Principal Investigator

- 3) The Response of Rat Na,K-ATPase to Pulmonary Edema  
#F32 HL08198; NIH National Research Service Award  
\$105,900; July 1990 - June 1993, Principal Investigator
- 3) Regulation of Type 2 Cell Proliferation During  
Hyperoxic Injury  
Roger Williams Cancer Center Developmental Grant  
\$15,000, Jan. 1992 - Dec. 1992, Principal Investigator
- 4) Characterization and Identification of a Novel,  
Constitutively Tyrosine-Phosphorylated Putative  
Growth Factor Receptor Present in Type 2 Pneumocytes  
and A549 Lung Carcinoma Cells.  
Roger Williams Cancer Center Biomedical Research  
Support Grant  
\$10,000, Jan. 1993 - Dec. 1993, Principal Investigator
- 6) Characterization of a Constitutively Phosphorylated  
Growth Factor Receptor A549 Cells  
Brown University Institutional American Cancer Society  
Grant, \$14,000; Feb. 1994 - Jan. 1995, Principal  
Investigator
- 7) Characterization of a Constitutively Phosphorylated  
Growth Factor Receptor on a Bronchoalveolar  
Carcinoma Cell Line  
Rhode Island Foundation  
\$5,000; Feb. 1995 - Jan. 1996, Principal Investigator
- 8) Modulation of Bleomycin-Induced Lung Injury Using the  
Antioxidant, Amifostine.  
Lifespan Developmental Award  
\$21,182; Nov. 1997 - Oct. 1998, Principal Investigator
- 9) Modulation of Lung Injury by antioxidants  
Sigma-Tau Pharmaceuticals  
\$150,000; July 1998 -June 2000, Co-Investigator  
PI- Paul Calabresi, M.D.
- 10) Effects of Taurolidine on Human Malignant  
Mesothelioma  
Carter-Wallace Pharmaceuticals  
\$150,000; June 2000 -Sept 2001, Co-Investigator  
PI- Paul Calabresi, M.D.

- 31) Effects of ST1481, a novel camptothecin, on thoracic tumors; Sigma-Tau Pharmaceuticals; \$300,000, Jan 2002-Dec 2003, Co-Investigator  
PI- Paul Calabresi, M.D.
- 32) Novel Chemotherapeutics in Malignant Mesothelioma; TJ Martell Foundation; \$80,000; Jan 2003-December 2003, Principal Investigator
- 33) A randomized, double-blind, double-dummy, parallel group trial comparing 12 weeks treatment with Tiotropium handihaler once daily to Combivent MDI 2 actuations qid in COPD patients currently prescribed Combivent MDI; Boehringer-Ingelheim; \$100,000; Aug 2006-Dec 2007, Principle Investigator.
- 34) VA Cooperative trial CSP #560- Bronchitis and Emphysema Advice and Training to Reduce Hospitalization (BREATH); June 2008-June 2011. Site Investigator #650. \$50,000/yr.
- 35) Readmission Risk for Patients with Chronic Obstructive Pulmonary Disease in the Department of Veterans Affairs; The University of Utah; \$4121; Sept 2014- Sept 2015, Consultant.
- 36) The Trajectory of Physical Activity following Pulmonary Rehabilitation; St. Francis Hospital, CT; \$3200; Dec 2014-Dec 2015; Site Investigator.
- 37) PROACT Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment; Puget Sound VA Health Care System 6/18- 6/22; Site Investigator #650
- 38) Achieving Appropriate, Safe, and Patient-Centered Lung Cancer Screening; Boston VA Health Care System 4/18-4/22; Site Investigator #650

**University Teaching Roles**  
**Brown University**

- 1991 - Group Discussion Leader, Pulmonary Pathophysiology (Biomed 281)
- In depth discussion of respiratory pathophysiology, using a problem based learning format
  - Six sessions per year; 2 hours per session (direct contact: 12 hours/year and preparation: 12 hours/year)
  - Eight to ten students per year
- 1991 - 2015 Preceptor, Orientation Course for Physical Diagnosis (Biomed 373)
- Instruction on physical examination of the respiratory system using personal demonstration
  - One session per year; 2 hours per session (direct contact)
  - Sixteen to twenty-four students per year
- 1999 -2003 Faculty Leader, Affinity Group Program (Biomed 0551)
- 12 sessions per year; 2 hour sessions (as per the Affinity Program Office, there is a total of 100 teaching hours per year consisting of direct contact plus workshops, training sessions, lectures/dinners)
- 2000-2012 Co-Facilitator, Workshop on Racial Diversity
- 2 hour session with incoming freshman class (direct contact)
  - 2 hour training session prior to workshop
- 2010- present Lecturer, Pulmonary Pathophysiology (Biomed 281)

**University Teaching Roles**  
**Non-Brown University**

- 1992-2001 Lecturer, University of Rhode Island- PharmD program Pulmonary Physiology (PHP 562)
- 2.5 hour lecture per year (direct contact plus 3 hours preparation per year)
  - 30-40 students
- 2001-2009 Lecturer, University of Rhode Island- PharmD program Foundations of Human Disease (PHP/BMS 409)



- Entire Pulmonary Curriculum: 8.75 hours of lecture time/year (direct contact); 30 hours preparation time
- 30-40 students per class

### **Hospital Teaching Roles**

1991 - 1995

Attending Physician, Medical/Surgical ICU, Roger Williams Medical Center

- Teaching/ work rounds 4.5 hours/day; 8 weeks/year
- Rounds are designed to teach the pathophysiology of organ failure and the diagnostic and therapeutic management of critically ill patients.
- Three didactic lectures per week
- Teams consist of medical residents, fellows and third year clerks

1991-1995

Resident Morning Report, Roger Williams Medical Center

- 4 sessions /month; 8 weeks per year
- 10-12 residents per session (1-2 hours direct contact per session)

1991 - 1995

Attending Physician, Pulmonary Consult Service, Roger Williams Medical Center

- Teaching/ work rounds 4 hours/day; 8 weeks/year
- Rounds are designed to teach the pathophysiology of pulmonary disease and the diagnostic and therapeutic management of pulmonary patients.
- Three didactic lectures per week
- Teams consist of medical residents, fellows and third year clerks

1995-1999

Director/ Creator, Pulmonary Rehabilitation Rotation, Brown University Pulmonary and Critical Care Fellowship Program

- authored comprehensive annotated curriculum for fellows (12 hours preparation)
- organized outpatient rotations for fellows at both inpatient and outpatient pulmonary rehabilitation facilities (1 fellow per rotation, 1-2 hours per week , 10 months per year)
- work rounds/ didactic sessions ( 2 hours per week direct contact, 2 hours per week preparation)

- 1995 - 2000      Attending Physician, Respiratory Care Unit, Rhode Island Hospital
- Teaching/ work rounds 4.5 hours/day; 8 weeks/year
  - Rounds are designed to teach the pathophysiology of organ failure and the diagnostic and therapeutic management of critically ill patients.
  - Three didactic lectures per week
  - Teams consist of medical residents, fellows and third year clerks
- 1995 - 2000      Attending Physician, Pulmonary Consult Service, Rhode Island Hospital
- Teaching/ work rounds 4 hours/day; 8 weeks/year
  - Rounds are designed to teach the pathophysiology of pulmonary disease and the diagnostic and therapeutic management of pulmonary patients.
  - Three didactic lectures per week
  - Teams consist of medical residents, fellows and third year clerks
- 1995-2004      Lecturer, Resident Noon Conference, Rhode Island Hospital / Miriam Hospital
- 1-2 sessions per year, 10-12 residents per session
  - topics in pulmonary pathophysiology (1 hour direct contact per session, 2 hours preparation per session)
- 2001-2004      Attending Physician, RISE Clinic, Miriam Hospital
- Ambulatory TB clinic, 6-12 four-hour sessions/yr
  - Involves housestaff and fellow teaching
- 2001-2004      Attending Physician, General Medicine Service, RIH
- Teaching/ work rounds 4 hours/day; 1 month/year
  - Rounds are designed to teach pathophysiology, diagnostic and therapeutic management of medical patients.
  - Three didactic lectures per week
  - Teams consist of medical residents, and third year clerks
- 2004- Present      Attending Physician, Medical/Surgical ICU, Providence VAMC
- Teaching/ work rounds 3 hours/day; 32 weeks/year

- Rounds are designed to teach the pathophysiology of organ failure and the diagnostic and therapeutic management of critically ill patients.
- Teams consist of medical residents, fellows and third year clerks

2004-Present

Attending Physician, Pulmonary Consult Service, Providence VAMC

- Teaching/ work rounds 2 hours/day; 32 weeks/year
- Rounds are designed to teach the pathophysiology of pulmonary disease and the diagnostic and therapeutic management of pulmonary patients.
- Teams consist of medical residents, fellows and third year clerks

2004- Present

Lecturer, Resident Noon Conference, Providence VAMC

- 1 lecture every 2 months
- topics in pulmonary pathophysiology (1 hour direct contact per session, 2 hours preparation per session)